EPIDEMIOLOGY AND HEALTH DATA INSIGHTS
Review Article
Aug 30, 2026 4 2

Exploring the Potential of CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Malaria Resistance: A Systematic Review

Comfort Ohunene Matthew 1 * ,
Bassey Atte Inyang 2,
Verity Ghansah 3,
Blessing chinonye Nwadike 4,
Obinna Hilary Tony-Okpalaobi 5,
Anthony Kosisochukwu Anyabuoke 6
1 Department of Clinical Pharmacy, Faculty of Pharmacy, University of Benin, Benin City, Nigeria2 Department of Medical Biochemistry, College of Health Sciences, University of Abuja, FCT, Nigeria3 Department of Biology, New Mexico Institute of Mining and Technology, Socorro, NM, USA4 Department of Medical Laboratory Science, Faculty of Health Science, Imo State University, Owerri, Imo state, Nigeria5 Department of Internal Medicine, Federal Medical Center Jabi, Abuja, Nigeria6 Department of Biology, Columbus State University, Columbus, GA, USA* Corresponding Author
Epidemiology and Health Data Insights, 2(5), 2026, ehdi054, https://doi.org/10.63946/ehdi/19206
Publication date: Aug 30, 2026
Full Text (PDF)

ABSTRACT

Background: Sickle cell disease (SCD) and malaria remain major health challenges in sub-Saharan Africa. CRISPR-Cas9 has enabled advances in SCD gene therapy and malaria-related experimental research, but these applications represent distinct biological and translational pathways. This systematic review evaluated CRISPR-Cas9 applications in SCD and malaria research while distinguishing clinical therapeutic evidence from experimental malaria-related findings.
Methods: A systematic review was conducted following PRISMA 2020 and Joanna Briggs Institute guidance. PubMed, ScienceDirect and Google Scholar were searched on 12 August 2026. Studies investigating CRISPR-Cas9 applications related to SCD or malaria, including HBBcorrection, fetal haemoglobin induction, host-cell modification, parasite genome editing and mosquito-vector modification, were included. Data were synthesised narratively due to substantial heterogeneity among study designs and outcomes.
Results: Thirteen studies were included, comprising six SCD-related and seven malaria-related studies. SCD studies demonstrated progression from experimental genome correction and haemoglobin regulation strategies to clinical application of CRISPR-edited autologous haematopoietic stem and progenitor cells. Malaria-related studies primarily investigated parasite functional genomics, erythrocyte invasion mechanisms and mosquito genetic modification. No included study evaluated a single CRISPR-Cas9 intervention that simultaneously treated SCD and enhanced malaria resistance.
Conclusion: CRISPR-Cas9 represents an advancing therapeutic platform for selected SCD applications and an important experimental tool in malaria research. Current evidence supports separate translational pathways, with clinical progress established in SCD and malaria applications remaining predominantly preclinical.

KEYWORDS

CRISPR-Cas9 Sickle Cell Disease Malaria Resistance Gene Editing Genetic Therapies

CITATION (Vancouver)

Matthew CO, Inyang BA, Ghansah V, Nwadike BC, Tony-Okpalaobi OH, Anyabuoke AK. Exploring the Potential of CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Malaria Resistance: A Systematic Review. Epidemiology and Health Data Insights. 2026;2(5):ehdi054. https://doi.org/10.63946/ehdi/19206
APA
Matthew, C. O., Inyang, B. A., Ghansah, V., Nwadike, B. C., Tony-Okpalaobi, O. H., & Anyabuoke, A. K. (2026). Exploring the Potential of CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Malaria Resistance: A Systematic Review. Epidemiology and Health Data Insights, 2(5), ehdi054. https://doi.org/10.63946/ehdi/19206
Harvard
Matthew, C. O., Inyang, B. A., Ghansah, V., Nwadike, B. C., Tony-Okpalaobi, O. H., and Anyabuoke, A. K. (2026). Exploring the Potential of CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Malaria Resistance: A Systematic Review. Epidemiology and Health Data Insights, 2(5), ehdi054. https://doi.org/10.63946/ehdi/19206
AMA
Matthew CO, Inyang BA, Ghansah V, Nwadike BC, Tony-Okpalaobi OH, Anyabuoke AK. Exploring the Potential of CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Malaria Resistance: A Systematic Review. Epidemiology and Health Data Insights. 2026;2(5), ehdi054. https://doi.org/10.63946/ehdi/19206
Chicago
Matthew, Comfort Ohunene, Bassey Atte Inyang, Verity Ghansah, Blessing chinonye Nwadike, Obinna Hilary Tony-Okpalaobi, and Anthony Kosisochukwu Anyabuoke. "Exploring the Potential of CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Malaria Resistance: A Systematic Review". Epidemiology and Health Data Insights 2026 2 no. 5 (2026): ehdi054. https://doi.org/10.63946/ehdi/19206
MLA
Matthew, Comfort Ohunene et al. "Exploring the Potential of CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Malaria Resistance: A Systematic Review". Epidemiology and Health Data Insights, vol. 2, no. 5, 2026, ehdi054. https://doi.org/10.63946/ehdi/19206

SUPPLEMENTARY FILES

Supplementary File

REFERENCES

  1. World Health Organization [WHO]. Sickle-cell disease 2025. [cited 2026 Aug 12]. Available from: https://www.who.int/news-room/fact-sheets/detail/sickle-cell-disease
  2. World Health Organization [WHO]. World malaria report 2025. [cited 2026 Aug 12]. Available from: https://www.who.int/publications/i/item/9789240117822
  3. Silva R, Rodrigues A, Arez AP, Medeiros MM. Association between sickle cell trait and Plasmodium falciparum infection: evidence for age-specific protection in a cross-sectional study in Guinea-Bissau. International Journal of Infectious Diseases. 2025 Dec 1;161:108135. doi:10.1016/j.ijid.2025.108135
  4. Wilkinson AC, Dever DP, Baik R, Camarena J, Hsu I, Charlesworth CT, et al. Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice. Nat Commun. 2021 Jan 29;12:686. doi:10.1038/s41467-021-20909-x
  5. Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. N Engl J Med. 2021 Jan 21;384(3):252–60. doi:10.1056/NEJMoa2031054
  6. Sharma A, Boelens JJ, Cancio M, Hankins JS, Bhad P, Azizy M, et al. CRISPR-Cas9 Editing of the HBG1/HBG2 Promoters to Treat Sickle Cell Disease. N Engl J Med. 2023 Aug 31;389(9):820–32. doi:10.1056/NEJMoa2215643
  7. Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, et al. Exagamglogene Autotemcel for Severe Sickle Cell Disease. N Engl J Med. 2024 May 9;390(18):1649–62. doi:10.1056/NEJMoa2309676
  8. Kanjee U, Grüring C, Chaand M, Lin KM, Egan E, Manzo J, et al. CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants of Plasmodium falciparum invasion. Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):E9356–65. doi:10.1073/pnas.1711310114
  9. Jonsdottir TK, Paoletta MS, Ishizaki T, Hernandez S, Ivanova M, Herrera Curbelo A, et al. A scalable CRISPR-Cas9 gene editing system facilitates CRISPR screens in the malaria parasite Plasmodium berghei. Nucleic Acids Res. 2025 Jan 22;53(2):gkaf005. doi:10.1093/nar/gkaf005
  10. Gantz VM, Jasinskiene N, Tatarenkova O, Fazekas A, Macias VM, Bier E, et al. Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi. Proceedings of the National Academy of Sciences. 2015 Dec 8;112(49):E6736–43. doi:10.1073/pnas.1521077112
  11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi:10.1136/bmj.n71
  12. Joanna Briggs Institute [JBI]. JBI Evidence Synthesis Manual 2024 | PDF | Systematic Review | Evidence [Internet]. [cited 2026 Aug 12]. Available from: https://www.scribd.com/document/727084554/JBI-Manual-for-Evidence-Synthesis-20
  13. Hoban MD, Lumaquin D, Kuo CY, Romero Z, Long J, Ho M, et al. CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells. Mol Ther. 2016 Sep;24(9):1561–9. doi:10.1038/mt.2016.148
  14. Frati G, Brusson M, Sartre G, Mlayah B, Felix T, Chalumeau A, et al. Safety and efficacy studies of CRISPR-Cas9 treatment of sickle cell disease highlights disease-specific responses. Mol Ther. 2024 Dec 4;32(12):4337–52. doi:10.1016/j.ymthe.2024.07.015
  15. Carrington E, Ballmer D, Niederwieser I, Thommen BT, Brancucci NMB, Voss TS. A heterologous marker-free selection approach for CRISPR/Cas9-based gene editing in the malaria parasite Plasmodium falciparum. mSphere. 2026 Mar 26;0(0):e00884-25. doi:10.1128/msphere.00884-25
  16. Nishi T, Shinzawa N, Yuda M, Iwanaga S. Highly efficient CRISPR/Cas9 system in Plasmodium falciparum using Cas9-expressing parasites and a linear donor template. Sci Rep. 2021 Sep 16;11:18501. doi:10.1038/s41598-021-97984-z
  17. Zhang C, Gao H, Yang Z, Jiang Y, Li Z, Xiao B, et al. CRISPR/Cas9 mediated sequential editing of genes critical for ookinete motility in Plasmodium yoelii. Mol Biochem Parasitol. 2017 Mar;212:1–8. doi:10.1016/j.molbiopara.2016.12.010
  18. Kumari G, Gupta P, Goswami SG, Jain R, Anand S, Biswas S, et al. CRISPR/Cas9-engineering of Kell null erythrocytes to unveil host targeted irresistible antimalarials. Commun Biol. 2025 May 11;8:730. doi:10.1038/s42003-025-07968-2
  19. Esrick EB, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF, et al. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med. 2021 Jan 21;384(3):205–15. doi:10.1056/NEJMoa2029392
  20. Leonard A, Tisdale JF. Gene therapy for sickle cell disease. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):542–7. doi:10.1182/hematology.2023000487
  21. Shaik MY, Divers S. Efficacy, Safety, and Treatment‐Delivery Feasibility of Autologous Gene Therapy for Sickle Cell Disease: A Systematic Review With Descriptive Synthesis of Clinical Trials [Internet]. doi:10.1111/ejh.70260
  22. Canadian Agency for Drugs and Technologies in Health. Clinical Review. In: Exagamglogene Autotemcel (Casgevy): Therapeutic area: Sickle cell disease: Reimbursement Review [Internet] [Internet]. Canadian Agency for Drugs and Technologies in Health; 2025 [cited 2026 Aug 12]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK614940/
  23. Yen A, Zappala Z, Fine RS, Majarian TD, Sripakdeevong P, Altshuler D. Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel. N Engl J Med. 2024 May 9;390(18):1723–5. doi:10.1056/NEJMc2313119
  24. Hammond A, Galizi R, Kyrou K, Simoni A, Siniscalchi C, Katsanos D, et al. A CRISPR-Cas9 gene drive system targeting female reproduction in the malaria mosquito vector Anopheles gambiae. Nat Biotechnol. 2016 Jan;34(1):78–83. doi:10.1038/nbt.3439
  25. World Health Organization [WHO]. Guidance framework for testing of genetically modified mosquitoes, second edition [Internet]. 2021 [cited 2026 Aug 12]. Available from: https://www.who.int/publications/i/item/9789240025233

LICENSE

Creative Commons License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.